MacroGenics : Corporate Overview 2025 05 15 (Post ZYNYZ approval)
MGNX
Published on 05/16/2025 at 09:30
Developing
Life-changing Medicines®
May 16, 2025
Promising
Pipeline
Multiple clinical studies underway
Broad Capabilities for Drug Conjugates
Experience in combining novel targets with differentiated drug-linker technology
Proprietary Platforms for Multispecifics
Flexible platforms with clinical and/or partner validation
Proven R&D
Track Record
Three approved products generated from our pipeline(a) fuel potential revenue
Resourced to
Deliver on Plan
$154M Cash as of 3/31/25, plus projected and anticipated future payments, should support cash runway into 2H2026(b)
(a) TZIELD® was sold to Provention Bio (Sanofi) and is marketed by Sanofi; ZYNYZ® was licensed to, and is marketed by, Incyte. MARGENZA® was sold to, and is marketed by, TerSera Therapeutics LLC.
(b) MacroGenics' cash, cash equivalents and marketable securities balance of $154.1 million as of March 31, 2025, combined with projected and anticipated future payments from its partners, supports the Company's cash runway into the second half of 2026.
Proprietary and Partnered Programs
Program
Target / Modality
Potential Indication(s)
Preclinical
Phase 1
Phase 2
Phase 3
Marketed
Partner
PROPRIETARY PROGRAMS
mCRPC (+docetaxel) Study:
Lorigerlimab
PD-1 × CTLA-4 / DART®
-
PROC/CCGC Study:
MGC026
MGC028
MGC030
B7-H3 / TOP1i ADC
Multiple Solid Tumors
-
ADAM9 / TOP1i ADC
Multiple Solid Tumors
-
Undisclosed / TOP1i ADC
Multiple Solid Tumors
-
PARTNERED PROGRAMS
MARGENZA ZYNYZ TZIELD MGD024
Bispecific
HER2 / Fc-Optim. mAb
HER2+ Metastatic Breast Cancer
PD-1 / mAb
MCC, SCAC, NSCLC
CD3 / mAb
T1DM (At Risk, Early Onset)
Multiple regulatory decisions expected 2H2025(a)
CD123 × CD3 / DART
CD123+ Heme Malignancies
Exclusive Option
TBA / DART or TRIDENT®
Multiple Solid Tumors
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. Pipeline reflects current status of each program or most recently completed phase of development.
(a) Anticipation of regulatory decisions disclosed by Sanofi in their "Results Q4 & FY 2024" (January 30, 2025).
Lorigerlimab
MGC026
MGC028
MGC030
MGD024
Function/ MoA
Simultaneous and/or independent blockade of two validated
checkpoint inhibitor molecules
Clinical
Results
Ph. 1 dose expansion results presented at ASCO-GU 2023:
Manageable safety profile in advanced solid tumors (n=127 patients
at dose of 6.0 mg/kg Q3W)
Preliminary evidence of durable anti-tumor activity in mCRPC population refractory to chemo and ARAT (confirmed ORR = 25.7%, confirmed PSA50 response rate = 28.6%)
Program
Activities
LORIKEET Phase 2 study in mCRPC fully enrolled
IDMC recommended that study may continue as planned (Feb 2025)
Expect to provide a clinical update in 2H2025
Initiated LINNET Phase 2 study in ovarian cancer
PD-1
PD-1
IgG4
ARAT=androgen receptor axis-targeted agent (abiraterone, enzalutamide or apalutamide)
Lorigerlimab (formerly MGD019) is investigational and has not yet been approved for marketing by any regulatory authority
ASCO-GU 2023 (Luke, et al., #155); 12/12/22 data cut-off
Disclaimer
MacroGenics Inc. published this content on May 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 16, 2025 at 13:29 UTC.